Azurity Archives
News and events as they happenAZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension)
Woburn, Mass. – September 2, 2022 – Azurity Pharmaceuticals, Inc., a private pharmaceutical company focused on developing innovative dose-forms and formulations of products to serve the needs of overlooked…
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF ZONISADE™ (zonisamide oral suspension)
Woburn, Mass. – July 18, 2022 – Azurity Pharmaceuticals, Inc., a private pharmaceutical company focused on developing innovative products to serve the specific needs of overlooked…
Azurity Pharmaceuticals Announces Richard Blackburn as New CEO
Woburn, Mass. – February 18, 2022 – Azurity Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing innovative medicines that meet the specific needs of underserved…
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF FLEQSUVY™
(baclofen oral suspension)
WOBURN, MA, February 7, 2022 Azurity Pharmaceuticals, Inc., a private specialty pharmaceutical company, focused on developing innovative products to meet the unique needs of patients with underserved…